Related Experiment Video
Updated: May 27, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
[Cannabinoids for symptomatic therapy of multiple sclerosis]
L Husseini1, V I Leussink, C Warnke
1Neurologische Klinik, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Deutschland.
Der Nervenarzt
|November 15, 2011
Summary
Cannabinoids effectively treat spasticity in multiple sclerosis (MS) patients. Clinical studies confirm the efficacy of cannabis-based medicines, like Sativex, for managing this common MS symptom.
Area of Science:
- Neuroscience
- Pharmacology
Context:
- Spasticity is a frequent and challenging symptom in multiple sclerosis (MS).
- Current treatments for MS spasticity are often inadequate, leading some patients to explore cannabis for relief.
- Anecdotal evidence of cannabis benefits is supported by emerging research into cannabinoid biology.
Purpose:
- To review the current understanding of cannabinoid biology.
- To evaluate the efficacy of cannabinoids as a treatment for spasticity in multiple sclerosis patients.
Summary:
- Clinical studies, including randomized, double-blind, placebo-controlled trials, demonstrate the effectiveness of cannabinoids in reducing spasticity in MS.
- Sativex, a cannabis-derived medication containing delta-9-tetrahydrocannabinol and cannabidiol, is approved in Germany for treating MS-related spasticity.
- This review synthesizes current knowledge on cannabinoid mechanisms and their therapeutic value in managing MS symptoms.
Impact:
- Provides a scientific basis for the use of cannabinoids in managing MS spasticity.
- Highlights the therapeutic potential of cannabis-based treatments for neurological conditions.
- Informs clinicians and patients about evidence-based options for spasticity management in multiple sclerosis.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...